Evidence for an involvement of substance P, but not cholecystokinin-like peptides, in hexamethonium-resistant intestinal peristalsis.
It has previously been found that, in the presence of naloxone, the ganglionic blocking drug hexamethonium fails to completely block peristaltic motility in the isolated ileum of the guinea-pig. This hexamethonium-resistant peristaltic activity is coordinated by enteric nerves since it is abolished by tetrodotoxin. In the present study the neurotransmitter circuitry of this type of peristalsis was studied by means of specific antagonists. Atropine totally suppressed hexamethonium-resistant peristalsis. This type of peristalsis was also strongly inhibited by the tachykinin antagonist, spantide, if a concentration sufficient to antagonize neuronally located substance P receptors was employed. In contrast, the cholecystokinin antagonist, lorglumide, caused only a slight inhibition of hexamethonium-resistant peristalsis. Both substance P and the cholecystokinin-related peptide, ceruletide, potently stimulated the hexamethonium-resistant type of peristaltic activity. These data indicate that, after blockade of nicotinic acetylcholine receptors, tachykinins mediate neuroneuronal coordination of peristalsis whereas acetylcholine acting via muscarinic receptors may be primarily responsible for neuromuscular transmission. Cholecystokinin-like peptides appear to play a modulator rather than a mediator role in hexamethonium-resistant peristalsis.
Barthó
L
L
Department of Pharmacology, Medical School, University of Pécs, Hungary.
Holzer
P
P
Leander
S
S
Lembeck
F
F
D000818:Animals; D002766:Cholecystokinin / Q000502:physiology*; D004351:Drug Resistance; D005260:Female; D005730:Ganglionic Blockers / Q000494:pharmacology; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006168:Guinea Pigs; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology*; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D009270:Naloxone / Q000494:pharmacology; D010455:Peptides / Q000502:physiology*; D010528:Peristalsis / Q000187:drug effects*; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology
D005730:Ganglionic Blockers; D006584:Hexamethonium Compounds; D010455:Peptides; D013373:Substance P; D009270:Naloxone; D018738:Hexamethonium; D013779:Tetrodotoxin; D002766:Cholecystokinin; C042867:spantide